Reid Weyant Merryman MD

Physician

450 Brookline AveBoston, MA 02215
Phone+1 617-732-6089
Fax+1 617-732-5706

Dr. Merryman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Merryman's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2019
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2013 - 2016
Harvard Medical SchoolClass of 2013

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2013 - 2028
NH State Medical License 2024 - 2028
RI State Medical License 2022 - 2028
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL Start of enrollment: 2021 Jun 04
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma Start of enrollment: 2023 Jul 18
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Sponsor-Investigator, Principal Investigator
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
WITHDRAWN
PHASE1, PHASE2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.
Allison M Bock, Lei Feng, Ayushi Chauhan, Lorenzo Falchi, Reid Merryman
Blood Advances. 2026-08-25
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Jennifer L Crombie, Austin I Kim, Robert Redd, Nancy Bartlett, Victoria Patterson
Clinical Lymphoma, Myeloma & Leukemia. 2026-08-01
Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma.
Joseph G Schroers-Martin, Reid Merryman, Michael A Spinner, Austin Yeung, Cheryl Chang
Haematologica. 2026-07-02

Abstracts/Posters

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Reid W Merryman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

BEGEV Salvage Regimen Linked to High Complete Remission RatesFebruary 18th, 2020
Treatment with PD-1 Prior to Stem Cell Transplant Is Safe for Hodgkin Lymphoma PatientsDecember 9th, 2019
ASCO 2023: Lymphoma Research Could Change PracticeJune 28th, 2023